hepatitis

FDA stop sign
Biotech

FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months

The FDA has placed a partial hold on the PORTOLA trial evaluating the selective immunoproteasome inhibitor in 24 patients with autoimmune hepatitis.
James Waldron Nov 13, 2024 5:22am
cancer target detection radiopharma radio

Kezar drops solid tumor yet to prove its worth in phase 1 trial

Aug 14, 2024 5:09am
stock market down crash fail shares

Durect fails alcohol-associated hepatitis trial, plans phase 3

Nov 8, 2023 7:57am